natgillin/translations-raw huggingface dataset:
Box of 6 pipettes of 0.5 ml, 1 ml, 2 ml, 4 ml or 6 ml Not all pack sizes may be marketed.
Kutija sa 6 pipeta od 05 ml, 1 ml, 2 ml, 4 ml ili 6 ml Ne moraju sve veličine pakovanja biti u prometu.
Box of 6 pipettes.
Kutija s 6 pipeta.
BOX OF 6 X 8.8 MICROGRAMS SYRINGES + 6 X 22 MICROGRAMS SYRINGES
KUTIJA SA 6 X 8,8 MIKROGRAMA ŠTRCALJKI + 6 X 22 MIKROGRAMA ŠTRCALJKI
Box of 7, 14 or 28 tablets
Kutija s 7, 14 ili 28 tableta
BOX OF 84 PATCHES CONTAINING 2 BOXES OF 42 PATCHES
KUTIJA S 84 FLASTERA KOJA SADRŽI 2 KUTIJE S 42 FLASTERA
Box of diluent
Kutija s otapalom
Box of suspension
Kartonska kutija sa suspenzijom
Box with 1 vial of 10 ml (10 doses).
Kartonska kutija s 1 bočicom od 10 ml (10 doza).
Box with 10 or 50 vials of 1 ml (1 dose).
Kartonska kutija s 10 ili 50 bočica od 1 ml (1 doza).
Box with 10, or 50 vials of 1 ml Box with 1 vial of 10 ml
Kutija s 10 ili 50 bočica od 1ml Kutija s 1 bočicom od 10 ml
Box with 5, 10, 25 or 50 vials of 1 ml (1 dose).
Kartonska kutija s 5, 10, 25 ili 50 bočica od 1 ml (1 doza).
Box with 5, 10, 25 or 50 vials of 1 ml Box with 1 vial of 10 ml
Kutija sa 5, 10, 25 ili 50 bočica od 1ml Kutija sa 1 bočicom od 10 ml
Box, pack sizes of 1, 3, 4, 6 or 15 applicators
Kartonska kutija, veličinama pakovanja od 1, 3, 4, 6 ili 15 aplikatora.
BOX/OUTER CARTON
VANJSKO PAKIRANJE
Boxed statements as follows:
U okviru bit će navedeno sljedeće:
Boxes containing:
Kutije sadrže:
Boxes of 1 vial of 10 or 50 doses
Kutije s 1 bočicom od 10 ili 50 doza
Boxes of 12 or 24 single-use polyester/aluminium foil sachets, containing 250 mg of cream.
Kutija s 12 ili 24 vrećice od poliesterske/aluminijumske folije za jednokratnu uporabu s 250 mg kreme.
Brachial neuritis and Guillain-Barré Syndrome have been reported after administration of a tetanus toxoid containing vaccine
Brahijalni neuritis i Guillain-Barréov sindrom prijavljivani su nakon primjene cjepiva koje sadrži toksoid tetanusa.
Bradley, IL 60915 United States
Bradley, IL 60915 S.A.D.
Bradycardia
bradikardija produljenje QTc
Bradycardia
bradikardija, produljenje QTc
Bradycardia
bradikardije
bradycardia
Manje često
Bradycardia (abnormally low heart rate),
Bradikardija (neuobičajeno spori otkucaji srca),
Bradycardia (Bradycardia, Heart rate decreased, Sinus bradycardia).
Bradikardija (bradikardija, usporen rad srca, sinusna bradikardija).
Bradycardia (rare),
bradikardija,
Bradycardia <50 beats per minute (bpm)
Bradikardija < 50 otkucaja u minuti
Bradycardia Arial fibrillation
Bradikardija Fibrilacija atrija Atrioventrikularni blok
Bradycardia as an infusion related adverse reaction
Bradikardija kao nuspojava povezana s infuzijom
Bradycardia Atrial Fibrillation
Bradikardija Fibrilacija atrija Atrioventrikularni blok
Bradycardia below the following limits:
Bradikardija ispod sljedećih granica:
Bradycardia has been reported during clinical studies; therefore, use crizotinib with caution due to the risk of excessive bradycardia when used in combination with other bradycardic agents (e.g., non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, beta-blockers, clonidine, guanfacine, digoxin, mefloquine, anticholinesterases, pilocarpine) (see sections 4.2 and 4.4).
U kliničkim je ispitivanjima prijavljena bradikardija; stoga je, zbog rizika od prekomjerne bradikardije, potreban oprez kod primjene krizotiniba u kombinaciji s drugim lijekovima koji uzrokuju bradikardiju (npr. nedihidropiridinski blokatori kalcijevih kanala poput verapamila i diltiazema, beta- blokatori, klonidin, gvanfacin, digoksin, meflokin, antikolinesteraze, pilokarpin) (vidjeti dijelove 4.2 i 4.4).
Bradycardia is also a well-known pharmacological effect from systemic beta blocker treatment.
Bradikardija je također dobro poznati farmakološki učinak sistemskog liječenja beta-blokatorom.
Bradycardia may develop when alpha-2-agonists are used with sevoflurane.
Bradikardija može nastati kad se alfa-2-agonisti koriste sa sevofluranom.
Bradycardia QTc prolongation (see section 4.4)
bradikardija produljenje QTc intervala (vidjeti dio 4.4)
Bradycardia should be diagnosed if the heart rate declines by more than 30 bpm from baseline.
Ako otkucaji srca padnu za više od 30 otkucaja u minuti od početnih, mora se dijagnosticirati bradikardija.
Bradycardia was evaluated as a potential safety signal and 15 cases were reviewed.
Bradikardija je ocijenjena kao potencijalni sigurnosni signal i pregledano je 15 slučajeva.
bradycardia weight increase/risk of obesity
bradikardije povećanja tjelesne težine/rizika od pretilosti
Bradycardia –inducing calcium-channel blockers (diltiazem, verapamil, bepridil)
Bradikardija-inducira blokatore kalcijevih kanala (diltiazem, verapamil, bepridil)
Bradycardia*
bradikardija
Bradycardia**, cardiac arrest**, hypotension**, vasodilatation**
Bradikardija**, srčani zastoj**, hipotenzija**, vazodilatacija
Bradycardia, Cardiac arrhythmia (secondary to hypocalcaemia)
Bradikardija, srčana aritmija (zbog hipokalcemije)
bradycardia, cardiovascular disorder
bradikardija, kardiovaskularni poremećaj
bradycardia, palpitations
bradikardija, palpitacije
bradycardia, tachycardia
bradikardija,
bradycardia, tachycardia
bradikardija, tahikardija
bradycardia, tachycardia
poremećaj kretanja
Bradycardia, tachycardia, cyanosis
Bradikardija, tahikardija, cijanoza
Bradycardiaa (life-threatening consequences, urgent intervention indicated)
Bradikardijaa (posljedice opasne po život, indicirana hitna intervencija)
Bradycardiaa (symptomatic, may be severe and medically significant, medical intervention indicated)
Bradikardijaa (simptomatska, može biti teška i medicinski značajna, indicirana medicinska intervencija)
Bradycardiac
Bradikardijac
Bradycardiag (13%)
bradikardijag (13%)
Bradychardia
bradikardija
Bradykinesia Drooling Dysgeusia Parosmia
hipertonija, bradikinezija, slinjenje, disgeuzija, parosmija
Bradyphrenia Disturbance in attention Nystagmus Paraesthesia Speech disorder Tremor
bradifrenija, poremećaj pažnje, nistagmus, parestezije, poremećaj govora, tremor
BRAF mutations have been identified at a high frequency in specific cancers, including approximately 50% of melanoma.
BRAF mutacije identificirane su u visokoj učestalosti u određenim karcinomima, uključujući oko 50% melanoma.
BRAF V600E (Primary)
BRAF V600E (Primarni)
brain
mozak
Brain haemorrhage
Krvarenje u mozgu
Brain metastasis Stable brain metastasis
Metastaze u mozgu Stabilne metastaze u mozgu
Brain MRI should be performed in any patient presenting with seizures, confusion or altered mental status.
Svakom bolesniku u kojega se pojave napadaji, glavobolja, konfuzija ili promjene mentalnog statusa treba učiniti MR mozga.
Brain oedema
edem mozga
brain oedema, encephalopathy4, extrapyramidal disorder5, neuropathy peripheral, ataxia, hypoaesthesia, dysgeusia
edem mozga, encefalopatija4, ekstrapiramidni poremećaj5, periferna neuropatija, ataksija, hipoestezija, disgeuzija
Brain3
Mozak3
Brain: loss of memory
Mozak: gubitak pamćenja
Braised beef flavouring Povidone (E1201) Macrogol 400
Aroma pirjane govedine Povidon (E1201) Makrogol 400
Brampton Road Hampden Park
Brampton Road Hampden Park Eastbourne, East Sussex
Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK
Brampton Road Hampden Park Eastbourne, East Sussex
Brampton Road, Hampden Park, Eastbourne,
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG
Bravecto 112.5 mg (2–4.5 kg) Bravecto 250 mg (>4.5 –10 kg) Bravecto 500 mg (>10 –20 kg) Bravecto 1000 mg (>20 –40 kg) Bravecto 1400 mg (>40 –56 kg)
Bravecto 112,5 mg (2-4,5 kg) Bravecto 250 mg (>4,5 -10 kg) Bravecto 500 mg (>10-20 kg) Bravecto 1000 mg (>20-40 kg) Bravecto 1400 mg (>40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10 –20 kg) Bravecto 1000 mg chewable tablets for large dogs (>20 –40 kg) Bravecto 1400 mg chewable tablets for very large dogs (>40–56 kg)
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg) Bravecto 250 mg tablete za žvakanje za male pse (>4,5 -10 kg) Bravecto 500 mg tablete za žvakanje za srednje velike pse (>10-20 kg) Bravecto 1000 mg tablete za žvakanje za velike pse (>20-40 kg) Bravecto 1400 mg tablete za žvakanje za vrlo velike pse (>40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10–20 kg) Bravecto 1000 mg chewable tablets for large dogs (>20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs (>40–56 kg)
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg) Bravecto 250 mg tablete za žvakanje za male pse (>4,5-10 kg) Bravecto 500 mg tablete za žvakanje za srednje velike pse (>10-20 kg) Bravecto 1000 mg tablete za žvakanje za velike pse (>20-40 kg) Bravecto 1400 mg tablete za žvakanje za vrlo velike pse (>40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5–10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10–20 kg) Bravecto 1000 mg chewable tablets for large dogs (>20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs (>40–56 kg)
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg) Bravecto 250 mg tablete za žvakanje za male pse (>4,5 -10 kg) Bravecto 500 mg tablete za žvakanje za srednje velike pse (>10-20 kg) Bravecto 1000 mg tablete za žvakanje za velike pse (>20-40 kg) Bravecto 1400 mg tablete za žvakanje za vrlo velike pse (>40-56 kg)
Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg) Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs (>10 – 20 kg) Bravecto 1000 mg spot-on solution for large dogs (>20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs (>40 – 56 kg)
Bravecto 112,5 mg otopina za nakapavanje za vrlo male pse (2 - 4,5 kg) Bravecto 250 mg otopina za nakapavanje za male pse (>4,5 - 10 kg) Bravecto 500 mg otopina za nakapavanje za srednje velike pse (>10 - 20 kg) Bravecto 1000 mg otopina za nakapavanje za velike pse (>20 - 40 kg) Bravecto 1400 mg otopina za nakapavanje za vrlo velike pse (>40 - 56 kg)
Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg) Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs (>10 – 20 kg) Bravecto 1000 mg spot-on solution for large dogs (>20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs (>40 – 56 kg) fluralaner
Bravecto 112,5 mg otopina za nakapavanje za vrlo male pse (2 - 4,5 kg) Bravecto 250 mg otopina za nakapavanje za male pse (>4,5 - 10 kg) Bravecto 500 mg otopina za nakapavanje za srednje velike pse (>10 - 20 kg) Bravecto 1000 mg otopina za nakapavanje za velike pse (>20 - 40 kg) Bravecto 1400 mg otopina za nakapavanje za vrlo velike pse (>40 - 56 kg) fluralaner
Bravecto 112.5 mg spot-on solution for very small dogs (2-4.5 kg) Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs (>10 - 20 kg) Bravecto 1000 mg spot-on solution for large dogs (>20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs (>40 – 56 kg) fluralaner
Bravecto 112,5 mg otopina za nakapavanje za vrlo male pse (2 - 4,5 kg) Bravecto 250 mg otopina za nakapavanje za za male pse (>4,5 - 10 kg) Bravecto 500 mg otopina za nakapavanje za srednje velike pse (>10 - 20 kg) Bravecto 1000 mg otopina za nakapavanje za velike pse (>20 - 40 kg) Bravecto 1400 mg otopina za nakapavanje za vrlo velike pse (>40 - 56 kg)
Bravecto can only be obtained with a prescription.
VMP Bravecto izdaje se samo na liječnički recept.
Bravecto chewable tablets
Bravecto tablete za žvakanje
Bravecto chewable tablets for dogs
Bravecto tablete za žvakanje za pse
Bravecto chewable tablets should be administered in accordance with the following table (corresponding to a dose of 25–56 mg fluralaner/kg bodyweight within one weight band):
Bravecto treba primjenjivati u skladu sa sljedećom tablicom (odgovarajuća doza od 25–56 mg fluralanera/kg tjelesne mase unutar pojedine skupine):
Bravecto is a chewable tablet and is well accepted by most dogs.
Bravecto je tableta za žvakanje i većinom ju psi dobro prihvaćaju.
Bravecto is a veterinary medicine used to treat flea and tick infestations in dogs and cats.
Bravecto je veterinarsko-medicinski proizvod koji se koristi za liječenje infestacije pasa i mačaka krpeljima i buhama.
Bravecto is available as a spot-on solution in a pipette for use on dogs and cats and as chewable tablets for use in dogs.
VMP Bravecto dostupan je u obliku otopine za kapanje u pipeti za primjenu u pasa i mačaka te u obliku tableta za žvakanje za primjenu u pasa.
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25-56 mg fluralaner/kg body weight):
Bravecto treba primjenjivati u skladu sa sljedećom tablicom (odgovarajuća doza od 25 – 56 mg fluralanera/kg tjelesne mase unutar pojedine skupine):
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25–56 mg fluralaner/kg bodyweight within one weight band):
Bravecto se treba primjenjivati u skladu sa sljedećom tablicom (odgovarajuća doza od 25–56 mg fluralanera/kg tjelesne mase unutar pojedine skupine):
Bravecto should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight):
Bravecto treba primjenjivati u skladu sa sljedećom tablicom (odgovarajuća doza od 40 – 94 mg fluralanera/kg tjelesne mase unutar pojedine skupine):
Bravecto spot-on solution and the wet skin of a recently treated animal may be slightly irritating to skin and/or eyes.
Otopina Bravecto za kapanje i mokra koža nedavno tretirane životinje mogu biti blago nadražujući za kožu i/ili oči.
Bravecto spot-on solution should be kept away from heat, sparks, open flames or other fire sources as it is highly flammable.
Otopinu Bravecto za kapanje potrebno je držati dalje od topline, iskri, otvorenog plamena ili drugih izvora vatre jer je vrlo zapaljiva.
Bravecto tablets are given around the dog’s feeding time as a tablet of the appropriate strength for the dog’s bodyweight.
Tablete se daju u vrijeme hranjenja psa i to tako da se daje tableta odgovarajuće jačine u odnosu na tjelesnu težinu psa.
Bravecto was effective against fleas and ticks for up to 12 weeks after treatment, and was as effective as fipronil in terms of the percentage of dogs and cats as well as households free of fleas and ticks.
VMP Bravecto pokazao se djelotvornim protiv buha i krpelja do 12 mjeseci nakon primjene terapije i jednako djelotvornim kao fipronil u pogledu postotka pasa i mačaka te kućanstava bez buha i krpelja.
Bre ast-feeding
Dojenje
break of sac of fluid within the ovaries (ovarian cyst ruptured) breast swelling.
pucanje vrećice s tekućinom unutar jajnika (puknuće ciste na jajnicima) oticanje dojki.
Break off the cap
Odlomite zatvarač
Break off the tamper-proof plastic tip from the solvent syringe by snapping the perforation of the cap.
Odvojite sigurnosni plastični vršak sa štrcaljke s otapalom tako da slomite perforirani dio zatvarača.
Break off the top of the ampoule of solvent.
Otrgnite vrh ampule s otapalom.
Break off the white, tamper-resistant, plastic cap from the solvent syringe by bending at the perforation cap until it snaps off.
Odlomite bijeli, plastični zatvarač za zaštitu od otvaranja sa štrcaljke s otapalom tako što ćete ga savijati na perforiranom mjestu dok se ne odvoji.
BREAK SEAL
OVDJE OTVORITI
BREAK-MB was a multicentre, open-label, two-cohort, Phase II study designed to evaluate the intracranial response of dabrafenib in subjects with histologically confirmed (Stage IV) BRAF- mutation positive (V600E or V600K) melanoma metastatic to the brain.
BREAK-MB je bilo multicentrično otvoreno ispitivanje faze II, u dvije kohorte dizajnirano za procjenu intrakranijalnog odgovora na dabrafenib u ispitanika s histološki potvrđenim melanomom s metastazama u mozgu (stadij IV) i pozitivnom BRAF mutacijom (V600E ili V600K).
Break-through bleeding and spotting may occur during treatment.
Probojno krvarenje i točkasto krvarenje mogu se javiti tijekom liječenja.
breakdown of muscle fibers and pain in muscles (rhabdomyolysis), abnormal posture
pucanje mišićnih vlakana i bol u mišićima (rabdomioliza), nenormalno držanje
breakdown of muscle fibers and pain in muscles (rhabdomyolysis), abnormal posture an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown, joint swelling, muscle weakness
pucanje mišićnih vlakana i bol u mišićima (rabdomioliza), nenormalno držanje povišenje CPK (keratin fosfokinaza) u krvi, enzim koji se ponekad oslobađa uz pucanje mišića, oticanje zglobova, mišićna slabost
Breakdown of muscle fibers leading to other complications
kidanje mišićnih vlakana koje dovodi do drugih komplikacija
breakdown of muscle fibers resulting in the release of muscle fiber contents (myoglobin) into the bloodstream;
pucanje mišićnih vlakana što rezultira oslobađanjem sadržaja mišićnih vlakana (mioglobina) u krvotok;
breakdown of muscle fibres and pain in muscles (rhabdomyolysis), abnormal posture newborn babies born to mothers who have taken TREVICTA during pregnancy may experience side effects of the drug and/or withdrawal symptoms, such as irritability, slow, or sustained muscle contractions, shaking, sleepiness, breathing, or feeding problems a decrease in body temperature, dead skin cells at injection site, an ulcer at injection site.
pucanje mišićnih vlakana i bol u mišićima (rabdomioliza), nenormalno držanje novorođenčad čije su majke tijekom trudnoće uzimale lijek TREVICTA mogu doživjeti nuspojave lijeka i/ili simptome ustezanja, poput razdražljivosti, sporih ili kontinuiranih mišićnih kontrakcija, drhtanja, pospanosti, problema s disanjem ili hranjenjem sniženje tjelesne temperature, odumiranje stanica kože na mjestu injekcije, čir na mjestu injekcije.
breakdown of muscle fibres resulting in the release of muscle fibre contents (myoglobin) into the bloodstream;
pucanje mišićnih vlakana što rezultira oslobađanjem sadržaja mišićnih vlakana (mioglobina) u krvotok;
breakdown of muscle tissue
razgradnja mišićnog tkiva
breakdown of muscle tissue a worsening of liver disease after Lamivudine Teva is stopped or during treatment if the hepatitis B virus becomes resistant to Lamivudine Teva.
razgradnja mišićnog tkiva pogoršanje jetrene bolesti nakon prekida liječenja lijekom Lamivudin Teva ili tijekom terapije u slučaju pojave rezistencije na Lamivudin Teva.
breakdown of muscle tissue a worsening of liver disease after Zeffix is stopped or during treatment if the hepatitis B virus becomes resistant to Zeffix.
razgradnja mišićnog tkiva pogoršanje jetrene bolesti nakon prekida liječenja lijekom Zeffix ili tijekom terapije u slučaju pojave rezistencije na Zeffix.
breakdown of muscle tissue liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis).
razgradnja mišićnog tkiva jetreni poremećaji, poput žutice, povećane ili masne jetre, upale (hepatitis).
breakdown of muscle, muscle pain or weakness
oštećenje mišića, bol ili slabost u mišićima
breakdown of muscle, muscle pain or weakness
propadanje mišića, bolovi u mišićima ili slabost mišića
Breakdown of muscle, muscle pain or weakness
raspad mišića, mišićni bolovi ili slabost
breakdown of red blood cells (haemolytic anaemia)
raspadanje crvenih krvnih stanica (hemolitička anemija)
breaking of finger nails and toe nails
lomljenje noktiju na rukama i nogama
breaking of finger nails and toe nails;
lomljenje noktiju,
Breakpoints
Granične koncentracije
Breakpoints
Granične vrijednosti
Breakpoints EUCAST breakpoints
Granične vrijednosti EUCAST granične vrijednosti
Breakthrough Aspergillus infections were observed in 1 versus 7 patients, and proven or probable breakthrough Candida infections were observed in 4 versus 2 patients in the micafungin and fluconazole groups, respectively.
Proboj infekcije prouzročene Aspergillusom bile su opažene u jednog bolesnika u skupini koja je primala mikafungin nasuprot 7 bolesnika u skupini koja je primala flukonazol, a dokazane ili vjerojatne proboj infekcije prouzročene Candidom bile su opažene u 4 bolesnika u skupini koja je primala mikafungin nasuprot 2 bolesnika u skupini koja je primala flukonazol.
Breakthrough bleeding or spotting may occur.
Može doći do probojnog ili točkastog krvarenja.
Breakthrough IFI – Day 180
Pojava invazivne gljivične infekcije – 180. dan
Breakthrough pain comes on suddenly.
Probijajuća bol nastupa naglo.
Breakthrough pain is an additional sudden pain that occurs despite you having taken your usual opioid pain relieving medicines.
Probojna bol je dodatna iznenadna bol koja se javlja usprkos redovitoj terapiji opioidima za ublažavanje boli.
Breast
Povećanje dojki
breast (injection site)
dojka (mjesto injekcije)
Breast cancer
Adenokarcinom pankreasa
Breast cancer All severities n=254 ( 5%)
Karcinom dojke svi stupnjevi težine n=254 ( 5%)
Breast cancer Grades 3/4 n=254 ( 5%)
Karcinom dojke stupanj 3/4 n=254 ( 5% )
Breast cancer has been found more often in women who take combined hormonal contraceptives.
Rak dojke češće je primjećen u žena koje uzimaju kombinirane hormonske kontraceptive.
Breast cancer n=404 (1-5%) not previously reported in clinical trials
Karcinom dojke n=404 (1-5%) prethodno nezabilježeni u kliničkim ispitivanjima
Breast cancer resistance protein (BCRP)
Protein koji uzrokuje rezistenciju raka dojke na lijekove (BCRP)
breast cancer that is advanced (has started to spread) in women who have been through their menopause.
uznapredovalog raka dojke (koji se počeo širiti) u žena koje su u postmenopauzi.
Breast cancer which has spread to other parts of the body (this is called “metastatic” breast cancer).
Rak dojke koji se proširio na druge dijelove tijela (to se naziva metastatski rak dojke).
Breast cancer, melanoma, and squamous cell carcinoma of the oral cavity applications in adults:
Primjene u slučaju raka dojke, melanoma i karcinoma pločastih stanica oralne šupljine u odraslih:
breast cancer.
karcinom dojke.
Breast cancer/Ovarian cancer
Karcinom dojke/karcinom jajnika
Breast cancer:
Karcinom dojke
Breast complaints (including tenderness)
tegobe s dojkama (uključujući osjetljivost)
Breast complaints include tenderness, pain and/or engorgement and nipple pain
Tegobe s dojkama uključuju osjetljivost, bol i/ili nabreklost te bolne bradavice
Breast complaints1
tegobe s dojkama1
Breast density
Gustoća dojki
Breast development
rast dojki
Breast development, acne or weight gain.
Razvoj dojki, akne ili dobivanje na težini.
Breast discharge, abnormal breast growth, breast growth in males
iscjedak iz dojke, neuobičajen rast dojki, rast dojki u muškaraca
Breast discharge, abnormal breast growth, breast growth in males.
iscjedak iz dojke, neuobičajen rast dojki, rast dojki u muškaraca
breast discomfort, enlargement of the glands in your breasts, breast enlargement, vaginal discharge very low body temperature, chills, an increase in body temperature, feeling thirsty, symptoms of drug withdrawal, accumulation of pus caused by infection at injection site, deep skin infection, a cyst at the injection site, bruising at injection site.
nelagoda u dojkama, povećanje žlijezdi u dojkama, povećanje dojki, vaginalni iscjedak vrlo niska tjelesna temperatura, zimica, povišenje tjelesne temperature, osjećaj žeđi, simptomi zbog ustezanja lijeka, nakupljanje gnoja uzrokovano infekcijom na mjestu primjene injekcije, duboka infekcija kože, cista na mjestu injekcije, modrica na mjestu injekcije.
Breast disorders
poremećaj dojki
breast disorders
poremećaji dojki
Breast enlargement
Reaction
Breast enlargement has been observed with INCRELEX treatment.
Primijećeno je povećanje dojki kod liječenja INCRELEXOM.
breast enlargement in males
povećanje dojki u muškaraca
breast enlargement in men
povećanje dojki u muškaraca
breast enlargement in men symptoms of restless legs syndrome (an irresistable urge to move a part of the body, usually the leg, accompanied by uncomfortable sensations)
povećanje grudi u muškaraca simptomi sindrom nemirnih nogu (neodoljiva potreba za pomicanjem dijela tijela, obično noge, praćeno osjećajem nelagode)